We Just Had An Epiphany

Tag: investing

Graph depicting Shiller P/E ratio (see above) and showing the S&P 500 trades at twice its mean/median or close.

S&P 500 PE Ratio Hits 30: Is a 2026 Bear Market Black Swan Immersion Imminent?

With the S&P 500 trading at nearly twice its historical P/E average, valuations are stretched. Even a 20% drop wouldn’t make stocks cheap. Is 2026 the year gravity reasserts itself?

Read entire article

Tags: Bear Market 2026, BearMarket2026, Black Swan Events Finance, Black Swan Risk, BlackSwan, Capital Preservation, featured-epiphany, Financial Risk, FinancialLiteracy, FUNanc1al, FUNanc1al Edge, FUNanc1al Investing, FunStock Index, How to Invest During a Recession, hub-epiphany, hub-special-files, Investing, Long-Term Investing, Macro Investing, Market Bubble, Market Crash Triggers 2026, Market Cycles, MarketAnalysis, PersonalFinance, Portfolio Diversification Strategies 2026, Robert Shiller, S&P 500, S&P 500 Bear Market 2026, S&P500, Shiller P/E, Shiller PE Ratio Analysis, Stock Market Bubble Signs, Stock Market Valuation, StockMarketCrash, Uncorrelated assets, Wealth
DNA helix powering an upward chart with a VOXZOGO vial—symbolizing BioMarin’s rare-disease focus, growth momentum, and attractive valuation.

Funds and Analysts Love BioMarin Pharmaceutical (BMRN), A Rare Combo of Value and Growth Fighting Also Rare Genetic Diseases. Should You?

BioMarin is that rare biotech: profits, pipeline, and price discipline. VOXZOGO grows, margins expand, and catalysts stack—at a surprisingly modest valuation.

 

Read entire article

Tags: BioMarin, Biotech, Biotech Investing, Biotech Investments, Biotech Stocks, BiotechGrowth, BiotechHumor, BiotechInvesting, Biotechnology, Biotechnology Innovation, BiotechStocks, BiotechTurnarounds, BiotechValue, BMRN, Buy BMRN Stock, FUNanc1al, Funanc1al Edge, Funanc1al Investing, Gene Therapy, Investing, Rare Disease, ROCTAVIAN, Value + Growth, VOXZOGO